Floatz Rating
B58/100
Confidence
Indicative
Sponsor
GeNeuro Innovation SAS
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
54High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05049161CT.gov A Long-term Extension of Study GNC-401 | — | Terminated | — | — | — |
NCT04480307CT.gov Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis | — | Completed | — | — | — |
NCT03574428CT.gov Single Ascending Doses Study With GNbAC1 in Healthy Male Volunteers | — | Completed | — | — | — |
NCT01639300CT.gov Safety Study of GNbAC1 in Multiple Sclerosis Patients | — | Completed | — | — | — |
NCT01699555CT.gov First-in-Human Study With GNbAC1 in Healthy Volunteers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Temelimab (this asset) | GeNeuro Innovation SAS | P2 | B · 58 |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Fingolimod | Biogen | P4 | BB |
| Interferon ?1 (Human Fibroblast Protein Moiety) | Bayer | P4 | BB |
| Natalizumab | Biogen | P4 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Temelimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Relapsing-Remitting Multiple Sclerosis | — | P2 | B · 57 |
| Long COVID-19 | — | P2 | B · 57 |
| Type 1 Diabetes Mellitus | — | P2 | B · 57 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Temelimab in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-multiple-sclerosis-associated-retrovirus-viral-envelope-protein-human-mus-musculus-monoclonal-gnbac1-heavy-chain-disulfide-with-human-mus-musculus-monoclonal-gnbac1-kappa-chain-dimer-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →